M

ore than a dozen U.S. senators have asked the Trump administration to proceed “as soon as possible” with a rule that would punish drug makers for overcharging hospitals, clinics, and other providers for medicines purchased under the federal government’s 340B drug discount program.

The request comes after the Trump administration recently delayed implementation until July 2018, a move that followed previous delays and prompted fresh criticism that the White House was kowtowing to the pharmaceutical industry.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.